Paul Tudor Jones Cogent Biosciences, Inc. Transaction History

Tudor Investment Corp Et Al

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.01 - $9.04 $255,617 - $384,489	42,532 New	42,532 $358,000
Q4 2023 Feb 14, 2024	BUY	$4.06 - $10.08 $44,903 - $111,484	11,060 Added 23.55%	58,031 $341,000
Q3 2023 Nov 15, 2023	BUY	$9.69 - $13.34 $295,961 - $407,443	30,543 Added 185.92%	46,971 $457,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.24 $232,903 - $313,059	-23,645 Reduced 59.0%	16,428 $194,000
Q1 2023 May 15, 2023	BUY	$10.04 - $15.5 $54,888 - $84,738	5,467 Added 15.8%	40,073 $432,000
Q4 2022 Feb 14, 2023	BUY	$10.65 - $14.84 $368,553 - $513,553	34,606 New	34,606 $400,000

170

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $585M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.